Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Pituitary
Published in: Pituitary 3/2008

01-09-2008 | Case Report

Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline

Authors: Giovanna Aparecida Balarini Lima, Evelyn de Oliveira Machado, Cintia Marques dos Santos Silva, Paulo Niemeyer Filho, Mônica Roberto Gadelha

Published in: Pituitary | Issue 3/2008

Login to get access

Abstract

Pituitary apoplexy is a rare and life-threatening clinical condition caused by hemorrhage and/or infarction of the pituitary gland or adenoma. Although pituitary apoplexy is usually spontaneous, it has been associated with numerous precipitating factors, such as bromocriptine use. However, reports of pituitary apoplexy during cabergoline therapy are scarce. We report three patients with cystic macroprolactinomas who developed pituitary apoplexy during cabergoline treatment.
Literature
1.
Brougham M, Heusner AP, Adams RD (1950) Acute degenerative changes in adenomas of the pituitary body – with special reference to pituitary apoplexy. J Neurosurg 7:421–439PubMed
2.
Rovit RL, Fein JM (1972) Pituitary apoplexy: a review and repraisal. J Neurosurg 37:280–288PubMed
3.
Mohr G, Hardy J (1982) Hemorrhage, necrosis, and apoplexy in pituitary adenomas. Surg Neurol 18:181–189PubMedCrossRef
4.
Rolih CA, Ober KP (1993) Pituitary apoplexy. Endocrinol Metab Clin N Am 22:291–302
5.
Bonicki W, Kasperlik-Zaluska A, Koszewski W, Zgliczynski W, Wislawski J (1993) Pituitary apoplexy: endocrine, surgical and oncological emergency Incidence, clinical course and treatment with reference to 799 cases of pituitary adenomas. Acta Neurochir (Wien) 120:118–122CrossRef
6.
Pinheiro MM, Cukiert A, Salgado LR, Nery M, Goldman J, Pimentel F, Liberman B (1999) Asymptomatic apoplexy in pituitary tumors. Arq Neuro-Psiquiat 57:74–77
7.
Tamasawa N, Kurahashi K, Baba T, Hishita R, Murabayashi S, Kashiwamura H, Takebe K (1988) Spontaneous remission of acromegaly after pituitary apoplexy following head trauma. J Endocrinol Invest 11:429–432PubMed
8.
Reid RL, Quigley ME, Yen SS (1985) Pituitary apoplexy. A review. Arch Neurol 42:712–719PubMed
9.
Randeva HS, Schoebel J, Byrne J, Esiri M, Adams CB, Wass JA (1999) Classical pituitary apoplexy: clinical features, management and outcome. Clin Endocrinol (Oxf) 51:181–188CrossRef
10.
Eisberg LA (1977) Pituitary apoplexy. Association of degenerative change in pituitary adenoma with radiotherapy and detection by cerebral computed tomography. Am J Med 63:109–115CrossRef
11.
Otsuka F, Kageyama J, Ogura T, Makino H (1998) Pituitary apoplexy induced by a combined anterior pituitary test: case report and review of the literature. Endocr J 45:393–398PubMedCrossRef
12.
Levy A (2003) Hazards of dynamic testing of pituitary function. Clin Endocrinol (Oxf) 58:543–544CrossRef
13.
Alzetani A, Fisher C, Costa R, Ohri SK (2002) Ptose postcardiac surgery: a case of pituitary apoplexy. Ann Thorac Surg 73:300–301PubMedCrossRef
14.
Maiza JC, Bennet A, Thom-Kany M, Lagarrigue J, Caron P (2004) Pituitary apoplexy and idiopathic thrombocytopenic purpura: a new case and review of the literature. Pituitary 7:189–192PubMedCrossRef
15.
Nagarajan DV, Bird D, Papouchado M (2003) Pituitary apoplexy following anticoagulation for acute coronary syndrome. Heart 89:10PubMedCrossRef
16.
Yamaji T, Ishibashi M, Kosaka K, Fukushima T, Hori T, Manaka S, Sano K (1981) Pituitary apoplexy in acromegaly during bromocriptine therapy. Acta Endocrinol (Copenh) 98:171–177
17.
Shirataki K, Chihara K, Shibata Y, Tamaki N, Matsumono S, Fujita T (1988) Pituitary apoplexy manifested during a bromocriptine test in a patient with a growth hormone- and prolactin-producing pituitary adenoma. Neurosurgery 23:395–398PubMedCrossRef
18.
Alhajje A, Lambert M, Crabbe J (1985) Pituitary apoplexy in an acromegalic patient during bromocriptine therapy. Case report. J Neurosurg 63:288–292PubMed
19.
Pinto G, Zerah M, Trivin C, Brauner R (1998) Pituitary apoplexy in an adolescent with prolactin-secreting adenoma. Horm Res 50:38–41PubMedCrossRef
20.
21.
Yahagi N, Nishikawa A, Matsui S, Komoda Y, Sai Y, Amakata Y (1992) Pituitary apoplexy following cholecystectomy. Anaesthesia 47:234–236PubMedCrossRef
22.
Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R, Joplin G, Robbins RJ, Tyson J, Thorner MO (1985) Bromocriptine as primary medical therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 60:698–705PubMed
23.
Molitch ME (1999) Medical treatment of prolactinomas. Endocrinol Metab Clin N Am 28:143–169CrossRef
24.
Bevan JS, Webster J, Christopher WB (1992) Dopamin agonist and pituitary tumor shrinkage. Endocr Rev 13:220–240PubMedCrossRef
25.
Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet CP, Jedynak CP, Kordon C, Peillon F, Jaquet P, Enjalbert A (1989) Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 69:500–509PubMed
26.
Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (1994) for the Cabergoline Comparative Study Group. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 331:904–909PubMedCrossRef
27.
Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, Annunziato L, Lombardi G (1997) Prolactinomas resistant to dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 82:876–883PubMedCrossRef
28.
Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84:2518–2522PubMedCrossRef
29.
Biller BM, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA, Schoenfelder JR, Klibanski A (1996) Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 81:2338–2343PubMedCrossRef
30.
Knoepfelmacher M, Gomes MC, Melo ME, Mendonça BB (2004) Pituitary apoplexy during therapy with cabergoline in an adolescent male with prolactin-secreting macroadenoma. Pituitary 7:83–87PubMedCrossRef
31.
Ebersold MJ, Laws ERJr, Scheithauer BW, Randall RV (1983) Pituitary apoplexy treated by transsphenoidal surgery. A clinicopathological and immunocytochemical study. J Neurosurg 58:315–320PubMed
32.
Arafah BM, Harrington JF, Madhoun ZT, Selman WR (1990) Improvement of pituitary function after surgical decompression for pituitary tumor apoplexy. J Clin Endocrinol Metab 71:323–328PubMed
33.
Bills DC, Meyer FB, Laws ER Jr, Davis DH, Ebersold MJ, Scheithauer BW, Ilstrup DM, Abboud CF (1993) A retrospective analysis of pituitary apoplexy. Neurosurgery 33:602–608PubMedCrossRef
34.
Maccagnan P, Macedo CL, Kayath MJ, Nogueira RG, Abucham J (1995) Conservative management of pituitary apoplexy: a prospective study. J Clin Endocrinol Metab 80:2190–2197PubMedCrossRef
35.
Ayuk J, McGregor EJ, Mitchell RD, Gittoes NJL (2004) Acute management of pituitary apoplexy – surgery or conservative management? Clin Endocrinol (Oxf) 61:747–752CrossRef
36.
Wakai S, Fukushima T, Teramoto A, Sano K (1981) Pituitary apoplexy: its incidence and clinical significance. J Neurosurg 55:187–193PubMed
37.
38.
Enjalbert A, Bockaert J (1983) Pharmacological characterization of D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary. Mol Pharmacol 23:576–584PubMed
39.
De Camille P, Macconi P, Spada A (1979) Dopamine inhibits adenylate cyclase in human prolactin-secreting pituitary adenomas. Nature 278:252–254CrossRef
40.
Brocas H, Van Coevorden A, Seo H, Refetoff S, Vassart G (1981) Dopaminergic control of prolactin mRNA accumulation in the pituitary of the male rat. Mol Cell Endocrinol 22:25–30PubMedCrossRef
41.
Maurer RA (1981) Transcriptional regulation of the prolactin gene by ergocryptine and cyclic AMP. Nature 294:94–97PubMedCrossRef
42.
Shull JD, Gorski J (1990) Regulation of prolactin gene transcription in vivo: interactions between estrogen, pimozide, and alpha-ergocryptine. Mol Pharmacol 37:215–221PubMed
43.
Landolt AM, Minder H, Osterwalder V, Landolt TA (1983) Bromocriptine reduces the size of cells in prolactin-secreting pituitary adenomas. Experientia 39:625–626PubMedCrossRef
44.
Gen M, Uozumi T, Ohta M, Ito A, Kajiwara H, Mori S (1984) Necrotic changes in prolactinomas after long-term administration of bromocriptine. J Clin Endocrinol Metab 59:463–470PubMedCrossRef
45.
Mori H, Mori S, Saitoh Y, Arita N, Aono T, Uozomi T, Mogami H, Matsumoto K (1985) Effects of bromocriptine on prolactin-secreting pituitary adenomas Mechanism of reduction in tumor cell size evaluated by light and electron microscopic, immunohistochemical, and morphometric analysis. Cancer 56:230–238PubMedCrossRef
46.
Rengachary SS, Tomita T, Jefferies BF, Watanabe I (1982) Structural changes in human pituitary tumor after bromocriptine therapy. Neurosurgery 10:242–251PubMedCrossRef
47.
Tindall GT, Kovacs K, Horvath E, Thorner MO (1982) Human prolactin-producing adenomas and bromocriptine. A histological, immunocytochemical, ultrastructural, and morphometric study. J Clin Endocrinol Metab 55:1178–1183PubMed
48.
Barrow DL, Tindall GT, Kovacs K, Thorner MO, Horvarth E, Hoffman JC Jr (1984) Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors. J Neurosurg 60:1–7PubMedCrossRef
49.
Kovacs K, Stefaneanu L, Horvath E, Lloyd RV, Lancranjan I, Buchfelder M, Fahlbusch R (1991) Effect of dopamine agonist medication on prolactin producing pituitary adenomas. A morphological study including immunocytochemistry, electron microscopy and in situ hybridization. Virchows Arch A Pathol Anat Histopathol 418:439–446PubMedCrossRef
50.
Landolt AM, Osterwalder V (1984) Perivascular necrosis in prolactinomas: is it increased by bromocriptine?. J Clin Endocrinol Metab 58:1179–1183PubMed
51.
Lloyd HM, Meares JD, Jacobi J (1975) Effects of oestrogen and bromocriptine on in vivo secretion and mitosis in prolactin cells. Nature 255:497–498PubMedCrossRef
52.
Kontogeorgos G, Horvath E, Kovacs K, Coire C, Lloyd RV, Scheithauer BW, Smyth HS (2006) Morphologic changes of prolactin-producing pituitary adenomas after short treatment with dopamine agonists. Acta Neuropathol 111:46–52PubMedCrossRef
53.
Yousem DM, Arrington JA, James Zinhreich S, Kumar AJ, Nick Bryan R (1989) Pituitary adenomas: possible role of bromocriptine in intratumoral hemorrhage. Radiology 170:239–243PubMed
54.
Lundin P, Nyman R, Burman P, Lundberg PO, Muhr C (1992) MRI of pituitary macroadenomas with reference to hormonal activity. Neuroradiol 34:43–51CrossRef
55.
Delgrange E, Gustin T (2005) Cystic macroprolactinoma: primary medical treatment? Intern Med J 35:687–688PubMedCrossRef
Metadata
Title
Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline
Authors
Giovanna Aparecida Balarini Lima
Evelyn de Oliveira Machado
Cintia Marques dos Santos Silva
Paulo Niemeyer Filho
Mônica Roberto Gadelha
Publication date
01-09-2008
Publisher
Springer US
Published in
Pituitary / Issue 3/2008
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-007-0046-6

Other articles of this Issue 3/2008

Pituitary 3/2008 Go to the issue

OriginalPaper

Inter- and intra-observer variability in detection and progression assessment with MRI of microadenoma in Cushing’s disease patients followed up after bilateral adrenalectomy

OriginalPaper

Molecular pathogenesis of human prolactinomas identified by gene expression profiling, RT-qPCR, and proteomic analyses

Case Report

Triple jeopardy in the pituitary

Case Report

Metastatic pancreatic neuroendocrine tumor presenting as a pituitary space occupying lesion: a case report

Case Report

Acromegaly and anaplastic astrocytoma: coincidence or pathophysiological relation?

ReviewPaper

Does the type and severity of brain injury predict hypothalamo–pituitary dysfunction? Does post-traumatic hypopituitarism predict worse outcome?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits